What is Axsome Therapeutics's additional paid-in capital?

Axsome Therapeutics (AXSM) reported additional paid-in capital of $1.43B in Q1 2026.

How has Axsome Therapeutics's additional paid-in capital changed year-over-year?

Axsome Therapeutics's additional paid-in capital increased by 15.4% year-over-year, from $1.24B to $1.43B.

What is the long-term trend for Axsome Therapeutics's additional paid-in capital?

Over 5 years (2020 to 2025), Axsome Therapeutics's additional paid-in capital has grown at a 28.8% compound annual growth rate (CAGR), from $392.59M to $1.39B.

Axsome Therapeutics AXSM Additional Paid-In Capital

Additional Paid-In Capital at other companies

Eli LillyLLY

——

AbbVieABBV

——

Neurocrine BiosciencesNBIX

——

Jazz PharmaceuticalsJAZZ

——

Arrowhead ResearchARWR

——

ALN

Alnylam PharmaceuticalsALNY

——

Other financials

Income statement

See full

Revenue$191.2M+57.4%

Gross profit$176.5M+58.0%

Operating income-$63.4M-11.2%

Net income-$64.5M-8.6%

EPS (diluted)-$1.26-3.3%

Balance sheet

See full

Cash & equivalents$305.1M+1.4%

Total debt$219.9M+4.1%

Total equity$54.6M+2.6%

Total assets$713.6M+19.6%

Cash flow

See full

Operating cash flow-$20.7M+52.3%

CapEx$121.0K-64.2%

Free cash flow-$20.8M+52.4%

Valuation

See full

Market cap$12.89B+52.0%

Enterprise value$12.81B+52.9%

P/S18.2×-1.4×

Profitability

See full

Gross margin92.6%+1.1pp

Operating margin-24.4%-9.3pp

Net margin-26.6%-9.8pp

FCF margin-10.2%-3.9pp

Returns & leverage

See full

Return on equity-349.4%+109pp

Debt / equity4×+0.1×

Current ratio1.4×-0.6×

Where this comes from

Reported directly by Axsome Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.

The official record: Axsome Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Axsome Therapeutics's additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Axsome Therapeutics's additional paid-in capital?: Axsome Therapeutics (AXSM) reported additional paid-in capital of $1.43B in Q1 2026.
How has Axsome Therapeutics's additional paid-in capital changed year-over-year?: Axsome Therapeutics's additional paid-in capital increased by 15.4% year-over-year, from $1.24B to $1.43B.
What is the long-term trend for Axsome Therapeutics's additional paid-in capital?: Over 5 years (2020 to 2025), Axsome Therapeutics's additional paid-in capital has grown at a 28.8% compound annual growth rate (CAGR), from $392.59M to $1.39B.